Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Regional Outlook | Forecast 2022-2028
Immunoglobulins refer to the antibodies produced naturally by the body's
immune system and help fight infections and diseases. These glycoprotein
molecules generated by the plasma cells act as a critical component of the
body's immune response by identifying and binding to specific antigens like
viruses and bacteria while aiding in their destruction.
According to Triton Market Research's analysis, the Global Immunoglobulin Market was valued at $13616.82 million in 2021 and is expected to reach $21497.75 million by 2028, growing at a CAGR of 6.77% during the forecast
period of 2022-2028.
Click here to check out our blog on the Global Immunoglobulin Market
MARKET PERFORMANCE – DRIVERS,
CHALLENGES, AND TRENDS
During the forecast period, the market expansion
will likely be fueled by growth in the geriatric population, the prevalence of
immunodeficiency diseases and autoimmune disorders, and increasing research and
development activities.
The elderly population is at risk for increased immunodeficiency diseases and
the severity of certain infections. Also, aging is related to abnormalities
related to humoral immunity. In addition, with an increase in age, there is a
rise in the prevalence of different infections and cancers. Also, it is being
observed that autoimmune processes play a crucial role in developing a range of
pathological conditions like atherosclerosis. As per WHO, 1 (in 6) people
worldwide will be aged 60 years or more by 2030. Also, the population with age
60 years or older is projected to reach 1.4 billion by 2030 from 1 billion in
2020. Such factors result in market growth.
The market must overcome significant obstacles
like the high cost of therapy and the high risk of side effects due to the use
of immunoglobulin.
The cost of human immunoglobulin therapies is directly related to the type of
delivery method used and the site of care. According to the National Center for
Biotechnology Information, the average cost per intravenous immunoglobulin
infusion in the United States has been reported to be $ 9,720, and patients
receive 4.3 infusions per month on average. Therefore, the total intravenous
immunoglobulin costs would be $41,796 per month. The treatment may last up to a
few months owing to which the complete therapy becomes a costly process.
The rising preference for personalized medicine
is likely to have a positive impact on the growth of the global immunoglobulin
market during the forecast period. Patients across the
world are increasingly opting for personalized medicines owing to the wide
range of benefits it offers. Personalized medicine possesses the potential to
provide improved medication selection & targeted therapy, reduce adverse
effects, increase patient compliance, enhance cost-effectiveness, shift the
objective of medicine from reaction to prevention and also increase patient
confidence. All these factors are expected to further boost developments in the
use of immunoglobulins as personalized medicines.
Report scope can be customized per your requirements. Request For Customization
KEY GEOGRAPHIES COVERED:
• North America:
United States and Canada
• Europe: United
Kingdom, France, Germany, Spain, Italy, and Rest of Europe
• Asia-Pacific:
China, Japan, India, South Korea, ASEAN Countries, Australia & New Zealand,
and Rest of Asia-Pacific
• Latin America:
Brazil, Mexico, and Rest of Latin America
• Middle East and Africa: United Arab Emirates, Saudi Arabia, Turkey, South Africa, and Rest of
Middle East & Africa
SEGMENTATION ANALYSIS –
IMMUNOGLOBULIN MARKET:
• Market by Product:
o IgG
o IgA
o IgM
o IgE
o IgD
Immunoglobulin G is expected to dominate the
market during the forecast period. It is the most common antibody type found in blood circulation and
represents approximately 75% of serum antibodies in the human body.
Immunoglobulin G molecules are created and released by plasma B cells, and each
immunoglobulin G antibody has two paratopes. It is the only class of
immunoglobulin capable of crossing the placenta in humans and is largely
responsible for the protection of the newborn during the first months of life.
Immunoglobulin G is the principal antibody used in clinical diagnostics and
immunological research owing to its excellent specificity toward antigens and
relative abundance. Also, immunoglobulin G is the major immunoglobulin in lymph
fluid, blood, peritoneal fluid, and cerebrospinal fluid and a key player in the
humoral immune response. Serum immunoglobulin G in healthy humans presents
about 15% of total protein besides enzymes, albumins, other globulins, and many
more.
• Market by Delivery Mode:
o Intravenous
o Subcutaneous
o Intramuscular
Intravenous is expected to dominate the market
during the forecast period.
• Market by Application:
o Hypogamma Globulinemia
o Chronic
Inflammatory demyelinating polyneuropathy
o Primary
Immunodeficiency diseases
o Myasthenia
Gravis
o Multifocal
motor neuropathy
o Idiopathic
thrombocytopenic purpura (ITP)
o Inflammatory
Myopathies
o Specific
antibody deficiency
o Guillain-Barre
syndrome
o Other
Applications
• Market by End-user:
o Hospitals
& Clinics
o Homecare
• Market by Sales Channel:
o Hospital
pharmacy
o Specialty
pharmacy
o Other
Distribution Channels
COMPETITIVE LANDSCAPE:
The competitive landscape helps dive into data about the key players in
the Immunoglobulin market. The strategic initiatives for each of the
companies considered have been covered in detail.
Partnership (January 2022):
LFB Group and Kedrion
In 2022, LFB Group and Kedrion announced a
partnership to increase the availability of immunoglobulin (a plasma-derived
medicine) for patients across France.
Agreement (March 2020):
Grifols and Shanghai RAAS
In 2020, Grifols and Shanghai RAAS announced their strategic alliance to
promote the growth of plasma-derived products and diagnostic solutions across
China.
Key Benefits of the Report:
● Triton Market Research has a collective experience of 25-30 years
in the industry, with its analysts and experts encompassing the most infallible
research methodology for its market intelligence and industry analysis.
● Our research methodology helps in achieving a broader consensus of
the market size, shape, and industry trends within each industry segment.
● The strategy adopted in designing the research methodology
includes the amalgamation of the information assembled from primary and
secondary sources, with the assistance of analytical tools to construct the
forecast and predictive models.
● The scope of the market report comprises the current scenario of
the global immunoglobulin market, along with the detailed overview of the
industry outlook, market dynamics, segmentation analysis, regional outlook, and
competitive landscape for the period 2022-2028.
FAQs:
Q 1) Does this report include
the impact of covid-19 on the immunoglobulin market?
The market study has analyzed the impact of COVID-19 ON the
immunoglobulin market qualitatively and quantitatively.
Q 2) Which product type is
dominating?
Immunoglobulin G accounted for the largest market share in terms of
revenue in 2021 and is expected to dominate the market during the forecast
period.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL
IMMUNOGLOBULIN MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE IMMUNOGLOBULIN MARKET
2.2. KEY
INSIGHTS
2.2.1. DEVELOPMENT
OF NEW PURIFICATION METHODS
2.2.2. INCREASING
PREFERENCE FOR PERSONALIZED MEDICINES
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. KEY
MARKET STRATEGIES
2.6.1. PRODUCT
LAUNCHES & DEVELOPMENTS
2.6.2. PARTNERSHIPS
& AGREEMENTS
2.7. MARKET
DRIVERS
2.7.1. GROWTH
IN THE GERIATRIC POPULATION
2.7.2. PREVALENCE
OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
2.7.3. INCREASING
RESEARCH AND DEVELOPMENT ACTIVITIES
2.8. MARKET
CHALLENGES
2.8.1. HIGH
COST OF THERAPY
2.8.2. HIGH
RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN
2.9. MARKET
OPPORTUNITIES
2.9.1. INCREASING
ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS
2.9.2. GROWING
CLINICAL TRIALS
3. GLOBAL
IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE
3.1. IGG
3.2. IGA
3.3. IGM
3.4. IGE
3.5. IGD
4. GLOBAL
IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE
4.1. INTRAVENOUS
4.2. SUBCUTANEOUS
4.3. INTRAMUSCULAR
5. GLOBAL
IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION
5.1. HYPOGAMMA
GLOBULINEMIA
5.2. CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY
5.3. PRIMARY
IMMUNODEFICIENCY DISEASES
5.4. MYASTHENIA
GRAVIS
5.5. MULTIFOCAL
MOTOR NEUROPATHY
5.6. IDIOPATHIC
THROMBOCYTOPENIC PURPURA (ITP)
5.7. INFLAMMATORY
MYOPATHIES
5.8. SPECIFIC
ANTIBODY DEFICIENCY
5.9. GUILLAIN-BARRE
SYNDROME
5.10. OTHER
APPLICATIONS
6. GLOBAL
IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER
6.1. HOSPITALS
& CLINICS
6.2. HOMECARE
7. GLOBAL
IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL
7.1. HOSPITAL
PHARMACY
7.2. SPECIALTY
PHARMACY
7.3. OTHER
SALES CHANNELS
8. GLOBAL
IMMUNOGLOBULIN MARKET – REGIONAL OUTLOOK
8.1. NORTH
AMERICA
8.1.1. MARKET
BY TYPE
8.1.2. MARKET
BY DELIVERY MODE
8.1.3. MARKET
BY APPLICATION
8.1.4. MARKET
BY END-USER
8.1.5. MARKET
BY SALES CHANNEL
8.1.6. COUNTRY
ANALYSIS
8.1.6.1. UNITED
STATES
8.1.6.2. CANADA
8.2. EUROPE
8.2.1. MARKET
BY TYPE
8.2.2. MARKET
BY DELIVERY MODE
8.2.3. MARKET
BY APPLICATION
8.2.4. MARKET
BY END-USER
8.2.5. MARKET
BY SALES CHANNEL
8.2.6. COUNTRY
ANALYSIS
8.2.6.1. UNITED
KINGDOM
8.2.6.2. GERMANY
8.2.6.3. FRANCE
8.2.6.4. SPAIN
8.2.6.5. ITALY
8.2.6.6. REST
OF EUROPE
8.3. ASIA-PACIFIC
8.3.1. MARKET
BY TYPE
8.3.2. MARKET
BY DELIVERY MODE
8.3.3. MARKET
BY APPLICATION
8.3.4. MARKET
BY END-USER
8.3.5. MARKET
BY SALES CHANNEL
8.3.6. COUNTRY
ANALYSIS
8.3.6.1. CHINA
8.3.6.2. JAPAN
8.3.6.3. INDIA
8.3.6.4. SOUTH
KOREA
8.3.6.5. ASEAN
COUNTRIES
8.3.6.6. AUSTRALIA
& NEW ZEALAND
8.3.6.7. REST
OF ASIA-PACIFIC
8.4. LATIN
AMERICA
8.4.1. MARKET
BY TYPE
8.4.2. MARKET
BY DELIVERY MODE
8.4.3. MARKET
BY APPLICATION
8.4.4. MARKET
BY END-USER
8.4.5. MARKET
BY SALES CHANNEL
8.4.6. COUNTRY
ANALYSIS
8.4.6.1. BRAZIL
8.4.6.2. MEXICO
8.4.6.3. REST
OF LATIN AMERICA
8.5. MIDDLE
EAST AND AFRICA
8.5.1. MARKET
BY TYPE
8.5.2. MARKET
BY DELIVERY MODE
8.5.3. MARKET
BY APPLICATION
8.5.4. MARKET
BY END-USER
8.5.5. MARKET
BY SALES CHANNEL
8.5.6. COUNTRY
ANALYSIS
8.5.6.1. UNITED
ARAB EMIRATES
8.5.6.2. SAUDI
ARABIA
8.5.6.3. TURKEY
8.5.6.4. SOUTH
AFRICA
8.5.6.5. REST
OF MIDDLE EAST & AFRICA
9. COMPETITIVE
LANDSCAPE
9.1. BIOTEST
AG
9.2. CHINA
BIOLOGIC PRODUCTS INC
9.3. GRIFOLS
SA
9.4. LFB
GROUP
9.5. CSL
BEHRING
9.6. KEDRION
BIOPHARMA
9.7. OCTAPHARMA
AG
9.8. TAKEDA
PHARMACEUTICAL COMPANY LIMITED
9.9. BIO
PRODUCTS LABORATORY
9.10. SHANGHAI
RAAS BLOOD PRODUCTS CO LTD
9.11. PFIZER
INC
9.12. SANQUIN
PLASMA PRODUCTS BV
9.13. ADMA
BIOLOGICS
9.14. SICHUAN
YUANDA SHUYANG PHARMACEUTICAL CO LTD
9.15. KAMADA
LTD
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: GLOBAL IMMUNOGLOBULIN
MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: GLOBAL IMMUNOGLOBULIN
MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 4: GLOBAL IMMUNOGLOBULIN
MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 5: GLOBAL IMMUNOGLOBULIN
MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 6: GLOBAL IMMUNOGLOBULIN
MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 7: GLOBAL IMMUNOGLOBULIN
MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 8: GLOBAL IMMUNOGLOBULIN
MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY
COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 15: EUROPE
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 16: EUROPE
IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 17: EUROPE
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 18: EUROPE
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 19: EUROPE
IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 20: EUROPE
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 21: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 24: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 27: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 28: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 29: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 30: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 32: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 33: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 34: MIDDLE EAST AND AFRICA
IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 35: MIDDLE EAST AND AFRICA
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 36: MIDDLE EAST AND AFRICA
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 37: MIDDLE EAST AND AFRICA
IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 38: MIDDLE EAST AND AFRICA
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: GLOBAL
IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)
FIGURE 3: GLOBAL
IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)
FIGURE 4: GLOBAL
IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)
FIGURE 5: GLOBAL
IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)
FIGURE 6: GLOBAL
IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)
FIGURE 7: GLOBAL IMMUNOGLOBULIN
MARKET, BY IGD, 2022-2028 (IN $ MILLION)
FIGURE 8: GLOBAL
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)
FIGURE 9: GLOBAL
IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)
FIGURE 10: GLOBAL
IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)
FIGURE 11: GLOBAL
IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)
FIGURE 12: GLOBAL
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)
FIGURE 13: GLOBAL
IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)
FIGURE 14: GLOBAL
IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY,
2022-2028 (IN $ MILLION)
FIGURE 15: GLOBAL
IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $
MILLION)
FIGURE 16: GLOBAL
IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)
FIGURE 17: GLOBAL
IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 18: GLOBAL
IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028
(IN $ MILLION)
FIGURE 19: GLOBAL
IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)
FIGURE 20: GLOBAL
IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $
MILLION)
FIGURE 21: GLOBAL IMMUNOGLOBULIN
MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)
FIGURE 22: GLOBAL
IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 23: GLOBAL
IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)
FIGURE 24: GLOBAL IMMUNOGLOBULIN
MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)
FIGURE 25: GLOBAL
IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)
FIGURE 26: GLOBAL
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)
FIGURE 27: GLOBAL
IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 28: GLOBAL
IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 29: GLOBAL
IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)
FIGURE 30: GLOBAL IMMUNOGLOBULIN
MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)
FIGURE 31: UNITED STATES
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: CANADA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: UNITED KINGDOM
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 34: GERMANY
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 35: FRANCE
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 36: SPAIN
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 37: ITALY
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 38: REST OF EUROPE
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 39: CHINA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 40: JAPAN
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 41: INDIA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 42: SOUTH KOREA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 43: ASEAN COUNTRIES
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 44: AUSTRALIA & NEW
ZEALAND IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 45: REST OF
ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 46: BRAZIL
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 47: MEXICO
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 48: REST OF LATIN
AMERICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 49: UNITED ARAB
EMIRATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 50: SAUDI ARABIA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 51: TURKEY
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 52: SOUTH AFRICA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 53: REST OF MIDDLE EAST
& AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
